Aggressive tumors, such as glioblastoma, remain difficult to manage due to high recurrence rates after treatment. Current diagnostic methods, including invasive biopsies and costly liquid biopsies, often delay detection and limit patient follow-up. 

A groundbreaking blood test now aims to change this by detecting cancer signals faster, more affordably, and with higher accuracy, potentially transforming the monitoring of the disease and treatment response. 

Australia-based OncoRevive, located in Victoria, developed a reagent kit that mixes with a patient’s blood sample to identify tumor biomarkers such as circulating DNA and proteins.

Utilizing artificial intelligence, this technology delivers results in under two hours and reduces costs by approximately 40% compared to conventional liquid biopsies. Unlike solid biopsies, the procedure is painless and does not require advanced clinical specialists. 

OncoRevive has already analyzed 100 patient samples in the United States and collaborates with universities to access biobanks for extensive validation. The test can detect cancer from a single circulating tumor cell, whereas current methods often require multiple cells for a positive result.

This increased sensitivity and accessibility could surpass traditional approaches for monitoring disease recurrence. 

OncoRevive initially focuses on breast cancer, with plans to expand to colon and other tumor types. The company is developing two products: a research kit for academic and clinical use and a clinical diagnostic kit.

To secure FDA and TGA approval, the company will expand testing to 700 patient samples. The research kit is expected to launch next year, with full approval projected for 2028, representing a significant advance in early detection and patient health management.